EVT.F - Evotec AG

Frankfurt - Frankfurt Delayed Price. Currency in EUR
20.28
+0.02 (+0.10%)
As of 5:22PM CEST. Market open.
Stock chart is not supported by your current browser
Previous Close20.26
Open20.22
Bid0.00 x 400000
Ask0.00 x 400000
Day's Range19.91 - 20.54
52 Week Range11.52 - 22.70
Volume15,729
Avg. Volume26,456
Market Cap3B
Beta0.70
PE Ratio (TTM)96.11
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • With An ROE Of 6.00%, Can Evotec AG (ETR:EVT) Catch Up To The Industry?
    Simply Wall St.13 days ago

    With An ROE Of 6.00%, Can Evotec AG (ETR:EVT) Catch Up To The Industry?

    I am writing today to help inform people who are new to the stock market and want to learn about Return on Equity using a real-life example. Evotec AG’s (ETR:EVT)Read More...

  • Updates on the Sanofi-Evotec Diabetes Business Collaboration
    Market Realist2 months ago

    Updates on the Sanofi-Evotec Diabetes Business Collaboration

    On June 25, Sanofi and Evotec reached the second milestone of the diabetes business alliance they entered into in August 2015, with a payment of 3 million euros from Sanofi to Evotec after the latter had met “pre-agreed critical success criteria for a potential manufacturing process” for generating human induced pluripotent stem cell-derived beta cells. The deal aims to extend Evotec’s metabolic disease and stem cell-based drug discovery programs and enhance Sanofi’s extensive diabetes research and development pipeline. According to the agreement, Evotec is eligible to receive as much as 300 million euros in milestone-based payments from Sanofi as well as royalties and research payments. To date, the company has received 9 million euros in upfront milestone-based payments and research funding from Sanofi.

  • Sanofi Signs Over Anti-Infectives Unit to Evotec
    Market Realist2 months ago

    Sanofi Signs Over Anti-Infectives Unit to Evotec

    On June 15, Sanofi (SNY) and Evotec, a Germany-based drug discovery and development company, signed an agreement to transfer Sanofi’s anti-infectives unit to Evotec for $70 million. Sanofi will also transfer 100 employees to Evotec and licenses for more than ten infectious disease R&D (research and development) pipeline assets.

  • Is It The Right Time To Buy Evotec AG (ETR:EVT)?
    Simply Wall St.2 months ago

    Is It The Right Time To Buy Evotec AG (ETR:EVT)?

    Evotec AG (ETR:EVT), a life sciences company based in Germany, received a lot of attention from a substantial price increase on the XTRA over the last few months. As aRead More...

  • Benzinga3 months ago

    Celgene Forges Oncology Partnership With Germany's Evotec

    Celgene Corporation (NASDAQ: CELG ) — which is recently very much in the news, although for dubious reasons — has struck a partnership with Germany's Evotec AG (ADR) (OTC: EVTCY ), which partners with ...

  • Does Evotec AG’s (ETR:EVT) -11.89% Earnings Drop Reflect A Longer Term Trend?
    Simply Wall St.3 months ago

    Does Evotec AG’s (ETR:EVT) -11.89% Earnings Drop Reflect A Longer Term Trend?

    After looking at Evotec AG’s (XTRA:EVT) latest earnings announcement (31 December 2017), I found it useful to revisit the company’s performance in the past couple of years and assess thisRead More...

  • Evotec AG (ETR:EVT): What Can We Expect From This High Growth Stock?
    Simply Wall St.4 months ago

    Evotec AG (ETR:EVT): What Can We Expect From This High Growth Stock?

    The latest earnings announcement Evotec AG’s (XTRA:EVT) released in December 2017 confirmed that the business endured a immense headwind with earnings declining by -11.89%. Below is a brief commentary onRead More...

  • What Does Evotec AG’s (ETR:EVT) Share Price Indicate?
    Simply Wall St.5 months ago

    What Does Evotec AG’s (ETR:EVT) Share Price Indicate?

    Evotec AG (XTRA:EVT), a life sciences company based in Germany, saw a significant share price rise of over 20% in the past couple of months on the XTRA. With manyRead More...

  • What You Must Know About Evotec AG’s (ETR:EVT) Return on Equity
    Simply Wall St.5 months ago

    What You Must Know About Evotec AG’s (ETR:EVT) Return on Equity

    Evotec AG’s (XTRA:EVT) most recent return on equity was a substandard 8.96% relative to its industry performance of 9.32% over the past year. EVT’s results could indicate a relatively inefficientRead More...